BCBS Louisiana Medical Policy Updates – November 2022

Click here to view the Blue Cross Blue Shield BCBS Louisiana Medical Policy Updates »

November 2022 BCBS Louisiana Medical Policy Updates:

• abaloparatide (Tymlos™)
• Ablation Procedures for Peripheral Neuromas
• Adjunctive Techniques for Screening and Surveillance of Barrett Esophagus and Esophageal Dysplasia
• Allograft Injection for Degenerative Disc Disease
• Amniotic Membrane and Amniotic Fluid
• Augmentative and Alternative Communication Devices
• Beta Interferons for the Treatment of Multiple Sclerosis
• Bioengineered Skin and Soft Tissue Substitutes
• Bisphosphonates (Oral)
• burosumab (Crysvita®)
• C1 Esterase Inhibitor (Berinert®)
• Catheter Ablation as Treatment for Atrial Fibrillation
• Chimeric Antigen Receptor T-cell (CAR-T) Therapy
• cladribine (Mavenclad®)
• Continuous Glucose Monitoring
• Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)
• Diabetic Test Strips
• Digital Health Therapies for Attention Deficit/Hyperactivity Disorder
• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, DPP-4 Inhibitor/Metformin Combination Drugs
• Drug Testing in Pain Management and Substance Use Disorder Treatment
• eltrombopag (Promacta®)
• etanercept (Enbrel®)
• Ethacrynic Acid Oral Products (Edecrin®, generics)
• Experimental-Investigational Services
• External Insulin Pump
• Gene Expression Profiling for Cutaneous Melanoma
• Genetic Testing for Diagnosis and Management of Mental Health Conditions
• Genetic Testing for Hereditary Hemochromatosis
• Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders
• Genotype-Guided Tamoxifen Treatment
• glatiramer acetate (Copaxone®)
• Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas
• Hippotherapy
• itraconazole (Onmel®)
• ivermectin tablets (Stromectol® ,generics)
• Laparoscopic and Percutaneous Techniques for the Myolysis of Uterine Fibroids
• Leadless Cardiac Pacemakers
• mepolizumab (Nucala®)
• Microprocessor-Controlled Prostheses for the Lower Limb
• mifepristone (Korlym®)
• modafinil (Provigil®)/armodafinil (Nuvigil®)
• Molecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus, and Solid Pancreaticobiliary Lesions
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Nutrient/Nutritional Panel Testing
• ofatumumab (Kesimpta®)
• Oncologic Applications of Photodynamic Therapy, Including Barrett’s Esophagus
• Orthopedic Applications of Stem Cell Therapy
• Pegylated Interferons (Pegasys® , PegIntron®) for Other (NonHepatitis C) Uses
• Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
• Pharmacotherapy for Gaucher Disease
• Phosphate Binders
• Photodynamic Therapy for Choroidal Neovascularization
• Risk-Reducing Mastectomy
• ruxolitinib (Opzelura™)
• Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
• Select Drug Quantity Management
• Select Drugs for Attention Deficit Hyperactivity Disorder (ADHD)
• Select Fenofibrate Products
• Select Levothyroxine Products
• Select Ophthalmic Prostaglandins
• Select Topical Rosacea Products
• Sensory Integration Therapy and Auditory Integration Therapy
• sipuleucel-T (Provenge®
• Sphingosine-1-Phosphate (S1P) Receptor Modulators (Gilenya®, Mayzent® , Zeposia® , Ponvory™)
• Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy
• Surgical Treatments for Breast Cancer−Related Lymphedema
• tafamidis Products (Vyndaqel®, Vyndamax™)
• teriflunomide (Aubagio®)
• Teriparatide Products
• Tetracyclines (oral)
• Treatment of Hepatitis C with a sofosbuvir (Sovaldi®) Based Regimen
• Treatment of Hepatitis C with elbasvir and grazoprevir (Zepatier®)
• Treatment of Hepatitis C with glecaprevir/pibrentasvir (Mavyret™)
• Treatment of Hepatitis C with ombitasvir, paritaprevir, ritonavir, and dasabuvir (Viekira Pak™)
• Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni®, Authorized Generic)
• Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®, Authorized Generic)
• Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adult Patients

Click here to view the Blue Cross Blue Shield BCBS Louisiana Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.